PIN73 FACTORS AFFECTING THE DECISION TO RECEIVE VACCINATION FOR INFLUENZA VIRUS H1N1  by Zavras, D & Kyriopoulos, J
13th Euro Abstracts A443
PIN69
OUTPATIENT ANTIBIOTIC USE IN PRIMARY HEALTH CARE IN NIS 
REGION
Kodela B1, Velickovic-Radovanovic R2, Petrovic J2, Mitic R2, Aleksic G1
1Pharmaceutical Institution of Nis, Nis, Serbia; 2Clinical Centre, Nis, Serbia
OBJECTIVES: Monitoring of antibiotic prescribing promotes rational use of drugs, 
reduces costs and slows down the development of resistance. The purpose of this study 
was to evaluate the prescribing of antibiotics in PHC of Niš region, during 2005–2009 
and to identify the practice of drug overuse, under-use or inappropriate use. 
METHODS: The data on outpatient use of antibacterials for systemic use was 
obtained by retrospective study and expressed as the number of deﬁ ned daily doses 
per 1000 inhabitants per day (DDD), according to WHO anatomic therapeutic chemi-
cal classiﬁ cation and DDD measurement methodology. The City Pharmacy Depart-
ment provided automatic reports on antibiotics prescribed by physicians for certain 
diagnoses in the Nis region over the 2005–2009 period. RESULTS: In the same period, 
outpatient antibiotic use in Nis region increased by 9.02% (22.83/ 25.96 DID). The 
most commonly prescribed drugs were semi-synthetics penicillins (9.67/10.00 DDD) 
and macrolides (3.05 /4.90 DDD). The greatest increase in antibiotics prescriptions 
was noted in azithromycin (0.26/0.70 DID, by 164%). Out of the total number of 
antibiotics, 70.5% prescriptions were made for treatment of URIs. Pharingitis ac. (J02) 
was the most common indication for prescription of antimicrobial medicines 
(45.26%). Amoxicillin (33%) and cephalexin (35%) were most commonly prescribed 
antibiotics for this indication. The total number of antibiotics prescriptions was 
increased by 14% while the cost was increased by 28% compared to 2005. CONCLU-
SIONS: Outpatient antibiotics use in Niš is high compared to the majority of European 
countries, which indicates the need for additional educational programs and monitor-
ing of microbiological sensitivity in future. The received results will be the basis for 
further evaluation of the rationality of use of antibiotics in primary health care.
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COST EQUITY ANALYSIS OF MALARIA MANAGEMENT: A PILOT 
STUDY IN THE AFRICAN SETTING
Espinoza MA1, Grifﬁ n S1, Cookson R2
1Centre for Health Economics, York, UK; 2Department of Social Policy and Social Work, 
York, UK
OBJECTIVES: To study the equity efﬁ ciency trade-off between decisions made based 
on maximization of health beneﬁ ts averaged for the whole population and decisions 
made considering the distribution of beneﬁ ts across socio economic groups of the 
population. METHODS: Cost-equity analysis nested in a CEA where ten different 
strategies for the management of patients with suspected non-complicated malaria 
were compared, in the African setting. Access to health clinics, access to treatment 
and adherence to the treatment were considered to vary between socio economic 
groups. a further hypothetical therapeutic alternative associated with 100% adherence 
for all groups was incorporated. Probabilistic sensitivity analysis was performed to 
reﬂ ect the uncertainty around parameter values. Inequality in the distribution of 
beneﬁ ts was estimated for each strategy using Concentration Indices (CI). The oppor-
tunity cost was estimated comparing the most cost-effective alternative against the 
most cost-equitable strategy in terms of health beneﬁ ts forgone to achieve a certain 
number of equality units. RESULTS: The most equitable strategy was also the most 
efﬁ cient for thresholds between US$137 and US$375 per DALY averted. Differences 
in equity of DALY burden between strategies were small (range CI units: 0.061–0.096) 
meaning the opportunity cost of choosing the most equitable strategy for threshold 
values outside of that range were relatively high, e.g. at US$400/DALY averted the 
opportunity cost was 0.11 DALYs per percentage point reduction in the CI. CON-
CLUSIONS: Equity concerns can be incorporated in the economic evaluation offering 
an estimation of the trade-off between efﬁ ciency and equity. Collection of information 
about access, adherence, effectiveness and costs according to socioeconomic group is 
required, but also information on prevalence for appropriate calculation of CI.
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CLINICAL AND ECONOMIC BURDEN OF PEDIATRIC INFLUENZA IN 
NINE EUROPEAN COUNTRIES
Rycroft C1, Leeuwenkamp O2, Heikkinen T3, Principi N4, Herz J5, Moren S6, Beard S7
1RTI Health Solutions, Manchester, UK; 2Formerly MedImmune Ltd, Cambridge, UK; 3Turku 
University Hospital, Turku, Finland; 4University of Milan, Milan, Italy; 5AstraZeneca, Zaventem, 
Belgium; 6MedImmune, LLC, Gaithersburg, MD, USA; 7RTI Health Solutions, Shefﬁ eld, UK
OBJECTIVES: Seasonal inﬂ uenza incurs a substantial clinical and economic burden 
in infants, children, and adolescents. The objectives of this literature review were to 
assess the reported incidence and complications of virologically-conﬁ rmed paediatric 
inﬂ uenza, and to evaluate the extent of health care utilization, absenteeism, direct 
health care costs, and societal costs in nine European countries: the United Kingdom, 
Germany, Italy, Spain, France, Sweden, the The Netherlands, Finland, and Austria. 
METHODS: A structured literature search (January 1970-March 2009) of PubMed, 
EMBASE, and the Cochrane Library was conducted. Data on inﬂ uenza burden in 
children (aged ≤15 years) were extracted from 43 publications. Of these, 13 articles 
presented data on virologically-conﬁ rmed inﬂ uenza. Pooled data from these 13 studies 
are presented. RESULTS: Data varied widely between countries. Median incidence of 
conﬁ rmed inﬂ uenza was 15.4% but ranged from 1.1 to 33.0% (n = 6 studies) in 
children aged ≤15 years. This wide range in incidence resulted from differences 
between studies in inﬂ uenza conﬁ rmation methods, age groups, and inﬂ uenza seasons. 
Complications due to inﬂ uenza were frequently reported (e.g., acute otitis media 
[range 0–40% [n = 7 studies]], pharyngitis [range 31–48% [n = 3 studies]]). In one 
study, a 3-fold increase in direct medical costs (c189–c206 vs. c59 [2004 costs]) was 
observed. In another study of children aged ≤1 year, hospitalization was reported to 
be the main driver of disease-related direct medical costs with hospitalization rates of 
about 20%. Of children with conﬁ rmed inﬂ uenza, 28–55% used antibiotics (n = 6 
studies) and 76–86% required antipyretics or symptomatic treatment (n = 5 studies). 
Conﬁ rmed inﬂ uenza in children was associated with 3–12 days’ absence from school/
daycare (n = 5 studies), and 1.3–6.3 days’ parental absence from work (n = 6 studies). 
CONCLUSIONS: The clinical and economic burden of virologically-conﬁ rmed pae-
diatric inﬂ uenza in Europe appears to be signiﬁ cant as revealed by incidence and 
associated morbidity and costs. This study was funded by MedImmune, LLC.
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BRAZILIAN STD/AIDS PROGRAMME: EXPENDITURE ON 
ANTIRETROVIRAL DRUGS AND EPIDEMIC INDICATORS DURING THE 
PERIOD 2004–2008
Aurea AP, Garcia LP, de Magalhaes LCG, dos Santos CF, de Almeida RF
Institute for Applied Economic Research, Brasilia, DF, Brazil
OBJECTIVES: The Brazilian STD/AIDS Programme stands out for ensuring universal 
and free access to antiretroviral drugs. We estimated the Federal expenditure on 
antiretroviral drugs of the Brazilian STD/AIDS Programme, during the period 2004–
2008, and compared it to epidemic indicators of the Brazilian population. METHODS: 
The expenditure on antiretroviral drugs comes from a data warehouse of the Ministry 
of Planning, Budget and Management that stores the information concerning any 
purchase made by the Brazilian Federal Government. The epidemiological indicators 
of AIDS are derived from the Brazilian STD/AIDS Programme, which combines data 
from different national information systems. RESULTS: The expenditure on antiret-
roviral drugs rose from US$144.416.113,57 in 2004, to US$333.050.295,64, in 2008. 
In Brazil, from January 2004 to June 2008, there were 148.852 cases of AIDS 
reported, which corresponds to an incidence rate of approximately 20 cases per 100 
thousand inhabitants. In the period from 2004 to 2007 there were 44.381 deaths due 
to AIDS in Brazil, representing a crude mortality ratio of about 6 deaths per 100 
thousand inhabitants. CONCLUSIONS: The use of antiretroviral drugs increases the 
survival of patients with HIV/AIDS and reduces the mortality rate. Despite the stability 
of AIDS incidence and mortality coefﬁ cients over the analyzed period, the expenditure 
increased, which can be due to an increase in coverage and range of drugs offered. As 
the resources are limited, it is important to understand the magnitude of the consump-
tion as well as the mechanisms of purchase in order to improve the supply of antiret-
roviral drugs.
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FACTORS INFLUENCING THE DECISION TO BE VACCINATED 
AGAINST H1N1 IN GREECE
Athanasakis K, Zavras D, Kyriopoulos J
National School of Public Health, Athens, Greece
OBJECTIVES: In view of the 2009 emergence of Inﬂ uenza a (H1N1) and the declara-
tion of a phase 6 pandemic by WHO, Greece established a voluntary vaccination 
program for the entire country population. The aim of the present study was to 
investigate factors affecting individuals’ decision to participate. METHODS: We con-
ducted repeated weekly telephone surveys until a random sample of 12,639 house-
holds stratiﬁ ed according to place of residence (geographical area and level of 
urbanization) was formulated. The interviews were based on a strictly structured 
questionnaire designed for the purpose of the study. a logistic regression analysis was 
conducted in order to identify the factors that inﬂ uence individuals’ decision to be 
vaccinated against H1N1. The Hosmer–Lemeshow criterion was used to check the 
model’s goodness of ﬁ t. RESULTS: Higher levels of personal education (Odds Ratio: 
0.61) and income (OR: 0.42) were associated with a negative decision to participate 
to the vaccination program. However, when an interaction term between the two 
variables was used, individuals of both higher education and income were more likely 
to have participated in the program (OR: 1.26). On the contrary, increased levels of 
concern/fear for the H1N1 and increased conﬁ dence to the personal/family physician, 
both measured in a 5-point Likert scale, showed a positive relationship. The Hosmer–
Lemeshow goodness of ﬁ t test statistic was 0.98 suggesting satisfactory ﬁ t of the 
model. CONCLUSIONS: In Greece, a country where less than 5% of the total popula-
tion participated to the voluntary vaccination program against H1N1, socioeconomic 
status, as expressed through income and education, the role of the family physician 
and the personal attitude towards H1N1 were important factors for a positive deci-
sion. In the case of similar future efforts, these variables should be taken into account, 
in order to facilitate focused interventions.
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FACTORS AFFECTING THE DECISION TO RECEIVE VACCINATION FOR 
INFLUENZA VIRUS H1N1
Zavras D1, Kyriopoulos J2
1National School of Public Health, Athens, Attiki, Greece; 2National School of Public Health, 
Athens, Greece
OBJECTIVES: The objective of this study was to determine factors affecting the 
population’s decision to get vaccinated against the inﬂ uenza H1N1 virus. METHODS: 
Data for this study was obtained from a Panhellenic survey, organized by the National 
School of Public Health of Greece. The sample (n = 12,639) was drawn from strata 
of various degrees of urbanization and geographical region. The primary outcome of 
the survey was the intent to get vaccinated for H1N1; logistic regression was used to 
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identify signiﬁ cant potential determinants. RESULTS: The decision of vaccination for 
inﬂ uenza virus H1N1 was associated with factors related to education, income, inter-
action between education and income, gender, trust to Public Health Organizations 
and perceptions about the health effects of inﬂ uenza virus H1N1. Individuals of higher 
education and income, do not intend to get vaccinated. This also holds for individuals 
who express low degree of trust to or believe that the H1N1 virus is not a serious 
threat to human health. CONCLUSIONS: We identiﬁ ed several socioeconomic and 
demographic factors affecting individual intent to get vaccinated for H1N1. Personal 
beliefs about the health effects of H1N1 virus and trust to Public Health Organizations 
were also signiﬁ cant predictors of vaccination intent.
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PARENTS’ DILEMMA WHETHER OR NOT TO VACCINATE THEIR 
CHILDREN AGAINST INFLUENZA A (H1N1)
Tsiantou V1, Zavras D2, Kyriopoulos J1
1National School of Public Health, Athens, Greece; 2National School of Public Health, 
Athens, Attiki, Greece
OBJECTIVES: In April 2009, WHO announced the emergence of Inﬂ uenza a (H1N1) 
and a phase 6 pandemic was declared a few months later. Vaccination was identiﬁ ed 
as an effective measure in order to eliminate the pandemic and ensure public health. 
The aim of the present study was to investigate the factors affecting parents’ decision 
to vaccinate their children. METHODS: A telephone survey was conducted in a random 
sample of 12,639 households stratiﬁ ed by geographical area using a strictly structured 
questionnaire designed for the purpose of the study. The survey lasted from October 
2009 to January 2010. a logistic regression analysis was conducted in order to identify 
the factors that inﬂ uence parents’ decision to vaccinate their children. The Hosmer–Lem-
eshow criterion was used to check the model’s goodness of ﬁ t. RESULTS: A total of 
3585 households were eligible and were included in the analysis. Education, income, 
concern about H1N1 and trust to the CDC were statistically signiﬁ cant. According to 
the analysis the higher the levels of education (OR 0.64) and income (OR 0.80) of the 
parents the lower the probability to vaccinate their children. However, the interaction 
term between education and income showed a positive relationship between these and 
the dependent variable. The greater the concern about H1N1 and the trust to the CDC 
the higher the probability for the parents to vaccinate their children. The Hosmer–Lem-
eshow goodness of ﬁ t test statistic was 0.52 suggesting satisfactory ﬁ t of the model. 
CONCLUSIONS: Based on our results concerns about the H1N1 and trust on the CDC 
were inﬂ uencing positively the decision for vaccination. The negative relationship 
between education and income and parents’ decision for vaccination was interesting and 
need further investigation. Results can explain the low vaccination rates against H1N1 
in Greece and can be used by policy makers to improve future vaccination campaigns.
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ESTIMATION OF PATIENTS WITH ANTIRETROVIRAL THERAPY 
POTENTIALLY USED FOR HIV PREVENTION (POST-EXPOSURE 
PROPHYLAXIS, MOTHER-TO-CHILD TRANSMISSION PROPHYLAXIS) IN 
GERMANY
Tomeczkowski J1, Guthoff-Hagen S2, Biteeva I1, Kruppert S3, Stoll M4
1Janssen-Cilag GmbH, Neuss, Germany; 2Sgh-Consulting, Hamburg, Germany; 3IMS Health 
GmbH & Co. OHG, Frankfurt/Main, Germany; 4Medical University of Hanover (MHH), 
Hannover, Germany
OBJECTIVES: Determine the number of patients who received antiretroviral therapy 
(ART) potentially prescribed for prevention of HIV infection in Germany in 2008. 
METHODS: A representative panel of 1,193,464 patients from different nationwide 
operating governmental sick funds were analyzed for 2008. Patients with a conﬁ rmed 
diagnosis of HIV (ICD-10: B20–24: 64,8%; R75: 0,9%; U85: 0,6%; U60–61: 14,9%; 
Z21: 18,8%) were included. In addition, an IMS pharmacy panel (LRx) with 26,815 
patients who had received ART identiﬁ ed by ATC Code J05C (Tenofovir was excluded 
because of use in Hepatitis) in October 2008 to September 2009 were analyzed (54% 
of all patients with ART-prescriptions). RESULTS: Sick funds: 927 patients with HIV 
diagnosis were identiﬁ ed (0.08% of the panel), 548 received an ART (treatment rate 
59.1%). Pharmacies: 46% of patients received an ART prescription in 4 quarters, 
16.9% in 3 quarters, 12.1% in 2 quarters and 24.9% in 1 quarter. 17.5% received 
prescriptions only on 1 day while of these patients 12% did not have any other ART 
prescription at least 4 months before or after the analysis period. Patients who received 
prescriptions on 1 day only, were younger, more often female and received more often 
Lopinavir/Ritonavir compared to patients who received prescriptions on more days. 
When extrapolating the numbers to the German governmentally insured population 
and comparing the numbers from sick funds of patients with a conﬁ rmed diagnosis 
receiving ART with patients who received an ART from pharmacies, about 30% of 
patients with ART prescription could not be matched to a conﬁ rmed diagnosis. 
CONCLUSIONS: Thirty percent of patients received ART prescriptions without con-
ﬁ rmed HIV diagnosis. Twelve percent of patients received ART prescriptions on one 
day only. Since these patients were younger, more often female and received agents 
more often used in prophylactic regimens, we assume that prescription of ART for 
prevention or post-exposure prophylaxis is likely in this group.
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THE USE OF ECONOMIC ANALYSIS IN VACCINE EXPERT REVIEWS
Jacobs P
Institute of Health Economics, Edmonton, AB, Canada
OBJECTIVES: Since the beginning of the new millennium, prices of vaccines have 
been increasing signiﬁ cantly, reﬂ ecting decades of research and development. As they 
have done with pharmaceuticals, governments have begun to incorporate economic 
considerations into scientiﬁ c reviews. Vaccines fall into the public health category, 
whose ethic differs historically from that in the pharmaceutical market. The purpose 
of this paper is to review how countries have incorporated economics into the scientiﬁ c 
vaccine review process. METHODS: We contacted experts in countries which had 
scientiﬁ c review committees according to the VENICE website, and the USA, Austra-
lia, New Zealand, and Hong Kong. We asked a series of questions regarding the 
structure of the review process, the role of economics, and the economic criteria used. 
RESULTS: We obtained information from ten countries which used economics in their 
vaccine scientiﬁ c reviews. In terms of structure, reviews fell into two groups—those 
which incorporated economics into the scientiﬁ c review (GB, FI, FR, HK, NL, NZ, US) 
and those which separated economic and clinical considerations (SW, AU). The criteria 
used in economic studies followed the pharmaceutical guidelines in all instances. CON-
CLUSIONS: Pharmaco-economics has grown up in the world of pharmaceuticals, not 
in the public health arena. The ethics in these two arenas differ. Certain elements—epi-
demiological considerations, herd immunity, long effect times—are relevant to vaccines. 
Using pharmacoeconomic rules for vaccines may not create a level playing ﬁ eld. 
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DO WE ADEQUATELY MODEL THE BENEFIT OF ROTAVIRUS 
VACCINATION OVER TIME?
Standaert B1, Gomez J2, Acosta-Rodriguez C3, Debrus S1
1GlaxoSmithKline Biologicals, Wavre, Belgium; 2GlaxoSmithKline Biologicals, Buenos Aires, 
Argentina; 3GlaxoSmithKline, Philadelphia, PA, USA
OBJECTIVES: Models estimating the impact of rotavirus vaccines over time use 
vaccine efﬁ cacy (VE) results from clinical trials measured at different time points. The 
formula to calculate VE measures diarrhea events observed in the vaccinated arm 
divided by events in the non-vaccinated arm during certain periods. Two problems 
occur: 1) the control arm builds up its own natural immunity over time: VE measured 
by the formula is therefore the net vaccine effect (NVE) that decreases as soon as the 
rate of infection increases; 2) natural immunity should be considered in the vaccinated 
arm as well as a booster phenomenon whereas this is generally omitted. How much 
will the cost-effectiveness result be impacted if natural immunity in the vaccinated arm 
is considered by improving the NVE-value over time? METHODS: A markov cohort 
model is used to measure the cost-effectiveness of vaccinating children at 2 and 3 
months against rotavirus infection in a country such as Panama as an example. The 
HE-model considers the health authority perspective, a life time horizon, and an 
annual discount rate of 3% on cost and effect. In sensitivity analysis the NVE decrease 
is varied over time post-vaccination from an annual linear 15% decrease to equal 
value post-2 doses. The outcome measure is the change in cost-effectiveness result in 
function of the variation in NVE-decrease. RESULTS: With the 15% decrease in NVE 
the QALY gain is 0.0124/person, the extra cost $2.46, and the ICER = $199/QALY 
gained. Improving the NVE to no decrease post-2 doses results in a QALY gain of 
0.0132 (+6%), an extra-cost of $0.98 (−99%), and an ICER reduction to $74/QALY 
gained. CONCLUSIONS: Assuming sustained VE over time because of natural immu-
nity in the vaccinated arm improves the economic results -especially the costs data. 
The gain will mainly occur post-disease peak after 2 years.
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ECONOMIC IMPACT OF INFLUENZA EPIDEMICS: MODELLING 
INTERACTIONS OF INFECTIONS, TREATMENT PATHWAYS AND 
REIMBURSEMENT
Einzinger P1, Zauner G2, Gyimesi M1, Schiller-Frühwirth I3, Pfeffer N3
1Vienna University of Technology, Vienna, Austria; 2Dwh Simulation Services, Vienna, Austria; 
3Main Association of Austrian Social Security Institutions, Vienna, Austria
OBJECTIVES: Infectious diseases spread through social contacts and affect people of 
all age groups. Traditional epidemic models consider these effects with the use of 
differential equations, contact networks or explicit modelling of households and 
workplaces. However past modelling studies did not implement structures of the 
health service system, like service providers (e.g. physicians) and their reimbursement. 
Therefore we investigate the integration of an epidemic contact model for inﬂ uenza 
into a framework for modelling treatment pathways and reimbursement of service 
providers. METHODS: The model framework is of object-oriented and agent based 
type. It incorporates patients and providers as spatially distributed agents. When 
patients develop diseases they search for service providers and treatment through a 
central health market, which in general returns one of the nearest providers of 
requested type. Each disease is connected to the possible treatment pathways and 
health services that a patient with the speciﬁ c disease will go through. In the study we 
incorporate inﬂ uenza epidemics occurring at speciﬁ ed time intervals. These epidemics 
spread through contacts of the agents modelled by a small-world network. Patients 
get immune after recovering and therefore one epidemic cannot infect them twice. The 
model calculates reimbursement from consumed health provider services and drugs. 
RESULTS: Modeled epidemics show the well-known behaviour of SIR-type models. 
Reduced capacity of service providers provokes that many patients do not consult 
them due to queuing effects. The model maps the development of costs over time 
plausibly. Different prescription probabilities of neuraminidase inhibitors inﬂ uence the 
course of the epidemic only marginally. CONCLUSIONS: The integration of epidemic 
models with models of health service processes and reimbursement can lead toward 
